New drug cocktail takes aim at tough lung cancer
NCT ID NCT07559929
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called DXC006 combined with either an immunotherapy drug (toripalimab) or standard chemotherapy (carboplatin or cisplatin) in 200 people with small cell lung cancer. The goal is to find the safest dose and see if the combination shrinks tumors or delays cancer growth. It is an early-stage trial, so the main focus is on safety and finding the right dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DXC006 (an experimental drug) combined with either an immune checkpoint inhibitor (toripalimab) or platinum-based chemotherapy (carboplatin or cisplatin)
- What this could lead to
- If successful, this could point toward a new combination treatment option for small cell lung cancer that may help control the disease longer.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with only 200 participants, so results may not apply to all patients. The experimental drug DXC006 may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can standard cancer treatment wake up the immune system? a study investigates.
- Experimental drug duo aims to boost immune attack on tough cancers
- Pinpoint radiation may spare the brain in lung cancer that spreads
- Rapid autopsy program aims to unlock secrets of aggressive lung cancer
- Mapping Cancer's evolution: a study to outsmart treatment resistance